文献速递临床试验与 GCP

经尿道微波热疗与前列腺动脉栓塞术缓解良性前列腺增生男性严重下尿路症状有效性的非劣效性随机开放标签临床试验:TUMT-PAE-1试验研究方案

Non-inferiority, randomised, open-label clinical trial on the effectiveness of transurethral microwave thermotherapy compared to prostatic artery embolisation in reducing severe lower urinary tract symptoms in men with benign prostatic hyperplasia: study protocol for the TUMT-PAE-1 trial.
PubMed 文献 · Trials · 2024-09-02

TUMT-PAE-1是一项多中心、非劣效性、开放标签随机临床试验,计划纳入223例良性前列腺增生伴严重下尿路症状的男性,1:1随机接受经尿道微波热疗或前列腺动脉栓塞术。主要终点为6个月时IPSS,非劣效性界值为+3分,采用95%CI评价。研究随访5年,旨在评估PAE是否非劣效于TUMT,并比较短期和长期的患者报告及功能结局。

要点

  • PAE对比TUMT的非劣效性界值设为IPSS +3分,主要终点为6个月IPSS。
  • 计划每组100例,考虑10%脱落,共纳入223例患者,随机比例1:1。
  • 随访5年,次要目标包括短期和长期患者报告及功能结局比较。

核心结论

  • 这是首个直接比较两种微创手术治疗的随机临床试验,研究者预期PAE非劣效于TUMT。
  • 研究者期望通过次要结局分析增进对疗效持久性的理解,并为治疗决策提供依据。

研究设计与样本

  • 多中心、非劣效性、开放标签随机临床试验,患者按1:1随机分配至TUMT或PAE。
  • 主要终点为6个月时两组IPSS,采用95%CI与预设非劣效性界值IPSS +3分比较。
  • 假设治疗后平均IPSS差异为1分、标准差为5,非劣效性界值设为临床无意义差异阈值+3分,计算每组样本量为100例。
  • 为补偿10%脱落,研究将纳入223例患者,随访5年以追踪长期疗效。

关键数值与推荐

  • 主要终点非劣效性界值为IPSS +3分,采用95%置信区间评价。
  • 样本量计算假设平均IPSS差异为1分,标准差为5,每组100例,考虑10%脱落共纳入223例。
  • 随访时间为5年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One-fourth of men older than 70 years have lower urinary tract symptoms (LUTS) that impair their quality of life. Transurethral resection of the prostate (TURP) is considered the gold standard for surgical treatment of LUTS caused by benign prostatic hyperplasia (BPH) that cannot be managed conservatively or pharmacologically. However, TURP is only an option for patients fit for surgery and can result in complications. Transurethral microwave thermotherapy (TUMT) and prostatic artery embolisation (PAE) are alternative minimally invasive surgical therapies (MISTs) performed in an outpatient setting. Both treatments have shown to reduce LUTS with a similar post-procedure outcome in mean International Prostate Symptom Score (IPSS). It is however still unknown if TUMT and PAE perform equally well as they have never been directly compared in a randomised clinical trial. The objective of this clinical trial is to assess if PAE is non-inferior to TUMT in reducing LUTS secondary to BPH. METHODS: This study is designed as a multicentre, non-inferiority, open-label randomised clinical trial. Patients will be randomised with a 1:1 allocation ratio between treatments. The primary outcome is the IPSS of the two arms after 6 months. The primary outcome will be evaluated using a 95% confidence interval against the predefined non-inferiority margin of + 3 points in IPSS. Secondary objectives include the comparison of patient-reported and functional outcomes at short- and long-term follow-up. We will follow the patients for 5 years to track long-term effect. Assuming a difference in mean IPSS after treatment of 1 point with an SD of 5 and a non-inferiority margin set at the threshold for a clinically non-meaningful difference of + 3 points, the calculated sample size was 100 patients per arm. To compensate for 10% dropout, the study will include 223 patients. DISCUSSION: In this first randomised clinical trial to compare two MISTs, we expect non-inferiority of PAE to TUMT. The most prominent problems with MIST BPH treatments are the unknown long-term effect and the lack of proper selection of candidates for a specific procedure. With analysis of the secondary outcomes, we aspire to contribute to a better understanding of durability and provide knowledge to guide treatment decisions. TRIAL REGISTRATION: ClinicalTrials.gov NCT05686525. Registered on January 17, 2023, https://clinicaltrials.gov/study/NCT05686525 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kristensen-Alvarez A, Fode M, Stroomberg HV, et al. Non-inferiority, randomised, open-label clinical trial on the effectiveness of transurethral microwave thermotherapy compared to prostatic artery embolisation in reducing severe lower urinary tract symptoms in men with benign prostatic hyperplasia: study protocol for the TUMT-PAE-1 trial. Trials. 2024. PMID: 39223593. doi:10.1186/s13063-024-08409-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。